Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 20/20 | 0.88 |
| ▸ | OXTR | P30559 | 12/20 | 0.88 |
| ▸ | AVPR2 | P30518 | 6/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.65 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.65 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835403 | 0.95 | AVPR1A (0.85) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4837407 | 0.94 | AVPR1A (0.90) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4835384 | 0.94 | AVPR1A (0.83) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL31737367 | 0.94 | AVPR1A (1.00) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2598091 | 0.94 | AVPR1A (1.00) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL29580282 | 0.93 | AVPR1A (0.99) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL5428661 | 0.93 | AVPR1A (0.99) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4697681 | 0.91 | AVPR1A (0.79) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL45615 | 0.91 | AVPR1A (0.84) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL45440 | 0.91 | AVPR1A (0.83) | AVPR1AOXTRAVPR2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | FEERING B.V. (NL) | 2005-02-10 | — | — | US | claimed |
| US-9125862-B2 | Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor | Institut National de la Sante et de la Rechereche Medicale (INSERM) (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20150005229-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | Institut National de la Sante et de la Rechereche Medicale (INSERM) (FR) | 2015-01-01 | — | — | US | disclosed |
| US-8853158-B2 | Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2014-10-07 | — | — | US | disclosed |
| US-20130102528-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | CHU DE TOULOUSE (FR) | 2013-04-25 | — | — | US | disclosed |
| WO-2011147889-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A FEEDING DISORDER WITH EARLY-ONSET IN A PATIENT | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-12-01 | — | — | WO | disclosed |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. | 2008-11-06 | — | — | US | disclosed |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. | 2008-11-06 | — | — | US | disclosed |
| US-7407949-B2 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2008-08-05 | — | — | US | disclosed |
| US-7407949-B2 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2008-08-05 | — | — | US | disclosed |
| US-7407949-B2 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2008-08-05 | — | — | US | disclosed |
| US-20060166971-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2006-07-27 | — | — | US | disclosed |
| EP-1592693-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | Ferring B.V. (NL) | 2005-11-09 | — | — | EP | disclosed |
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | FEERING B.V. (NL) | 2005-02-10 | — | — | US | disclosed |
| WO-2004072083-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | FERRING B.V. (NL) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004072083-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | FERRING B.V. (NL) | 2004-08-26 | — | — | WO | disclosed |
| EP-1449844-A1 | benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2004-08-25 | — | — | EP | disclosed |
| EP-1421087-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | OXTR, GNRHR, KISS1R | AVPR1A 8/4885OXTR 1/4885AVPR2 15/4885 |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885OXTR 4/4885AVPR2 2/4885 |
| US-20060166971-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885OXTR 4/4885AVPR2 2/4885 |
| US-20150005229-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | OXTR, OPRL1, GHRHR | AVPR1A 10/4885OXTR 1/4885AVPR2 12/4885 |
| US-20130102528-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | OXTR, OPRL1, GHRHR | AVPR1A 10/4885OXTR 1/4885AVPR2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.